FDA Clears Lumipulse Plasma Ratio as First Blood Test for Diagnosing Alzheimer Disease

The FDA approved Fujirebio’s Lumipulse G p-tau217/β-Amyloid 1-42 Plasma Ratio as the first in vivo blood test for early Alzheimer’s detection, demonstrating high diagnostic accuracy with strong correlations to amyloid PET and CSF test results.:

Source: Neurology Read More